Abstract:Abstract Background The trisaccharide 2 ′ -fucosyllactose (2 ′ -FL) is one of the most abundant oligosaccharides found in human milk. Due to its prebiotic and anti-infective properties, 2 ′ -FL is discussed as nutritional additive for infant formula. Besides chemical synthesis and extraction from human milk, 2 ′ -FL can be produced enzymatically in vitro and in vivo . The most promising approach for a large-scale formation of 2 ′ -FL is the whole cell biosynthesis in Escherichia coli by intracellular synthesis of GDP-L-fucose and subsequent fucosylation of lactose with an appropriate α1,2-fucosyltransferase. Even though whole cell approaches have been demonstrated for the synthesis of 2 ′ -FL, further improvements of the engineered E. coli host are required to increase product yields. Furthermore, an antibiotic-free method of whole cell synthesis of 2 ′ -FL is desirable to simplify product purification and to avoid traces of antibiotics in a product with nutritional purpose. Results Here we report the construction of the first selection marker-free E. coli strain that produces 2 ′ -FL from lactose and glycerol. To construct this strain, recombinant genes of the de novo synthesis pathway for GDP-L-fucose as well as the gene for the H. pylori fucosyltransferase futC were integrated into the chromosome of E. coli JM109 by using the λ-Red recombineering technique. Strains carrying additional copies of the futC gene and/or the gene fkp (from Bacteroides fragilis ) for an additional salvage pathway for GDP-L-fucose production were used and shown to further improve production of 2 ′ -FL in shake flask experiments. An increase of the intracellular GDP-L-fucose concentration by expression of fkp gene as well as an additional copy of the futC gene lead to an enhanced formation of 2 ′ -FL. Using an improved production strain, feasibility of large scale 2 ′ -FL production was demonstrated in an antibiotic-free fed-batch fermentation (13 l) with a final 2 ′ -FL concentration of 20.28 ± 0.83 g l -1 and a space-time-yield of 0.57 g l -1 h -1 . Conclusions By chromosomal integration of recombinant genes, altering the copy number of these genes and analysis of 2 ′ -FL and intracellular GDP-L-fucose levels, we were able to construct and improve the first selection marker-free E. coli strain which is capable to produce 2 ′ -FL without the use of expression plasmids. Analysis of intracellular GDP-L-fucose levels identified the de novo synthesis pathway of GDP-L-fucose as one bottleneck in 2 ′ -FL production. In antibiotic-free fed-batch fermentation with an improved strain, scale-up of 2 ′ -FL could be demonstrated.

High-Yield Synthesis of 2'-Fucosyllactose from Glycerol and Glucose in Engineered Escherichia coli.

Multi‐level metabolic engineering of Escherichia coli for high‐titer biosynthesis of 2′‐fucosyllactose and 3‐fucosyllactose

Efficient Production of 2'-Fucosyllactose from l-Fucose via Self-Assembling Multienzyme Complexes in Engineered Escherichia coli

Multi-Path Optimization for Efficient Production of 2′-Fucosyllactose in an Engineered Escherichia coli C41 (DE3) Derivative

High-Level De Novo Biosynthesis of 2′-Fucosyllactose by Metabolically Engineered Escherichia coli

Elimination of Byproduct Generation and Enhancement of 2'-Fucosyllactose Synthesis by Expressing a Novel α1,2-Fucosyltransferase in Engineered Escherichia coli.

Construction of an engineered Escherichia coli for effective synthesis of 2'-fucosyllactose via the salvage pathway

Metabolic Engineering of De Novo Pathway for the Production of 2′-Fucosyllactose in Escherichia coli

Enhanced production of 2'-fucosyllactose in engineered Escherichia coli BL21star(DE3) by modulation of lactose metabolism and fucosyltransferase

De novo synthesis of 2'-fucosyllactose in engineered Bacillus subtilis ATCC 6051a

De novo 2′‐fucosyllactose bioproduction through modular engineering of a novel <i>Escherichia coli</i> K12‐derived strain

Combinatorial metabolic engineering of Escherichia coli for de novo production of 2'-fucosyllactose

Improved production of 2'-fucosyllactose in engineered Escherichia coli by expressing putative α-1,2-fucosyltransferase, WcfB from Bacteroides fragilis

Engineering Escherichia coli MG1655 for Highly Efficient Biosynthesis of 2'-Fucosyllactose by De Novo GDP-Fucose Pathway

Improved production of 2'-fucosyllactose in engineered Saccharomyces cerevisiae expressing a putative α-1, 2-fucosyltransferase from Bacillus cereus

Metabolic engineering of Escherichia coli for the production of 2′-fucosyllactose and 3-fucosyllactose through modular pathway enhancement

Metabolic engineering strategies of de novo pathway for enhancing 2′‐fucosyllactose synthesis in Escherichia coli

Pathway Optimization of 2′-Fucosyllactose Production in Engineered Escherichia coli

Whole cell biosynthesis of a functional oligosaccharide, 2′-fucosyllactose, using engineered Escherichia coli

Engineering the Substrate Transport and Cofactor Regeneration Systems for Enhancing 2′-Fucosyllactose Synthesis in Bacillus subtilis

Construction of Escherichia coli strains with chromosomally integrated expression cassettes for the synthesis of 2′-fucosyllactose